



IFW

CASE D0284 NP

CERTIFICATE OF MAILING

I hereby certify that the paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico  
Type or print name

  
Signature

8-23-04  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

NADLER ET AL.

APPLICATION NO: 10/755,889

FILED: JANUARY 13, 2004

FOR: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH  
THE NF-KB PATHWAY

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: 8-23-04

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
 D0284 NP  
 APPLICATION NO.  
 10/755,889  
 APPLICANT  
 NADLER ET AL.  
 FILING DATE  
 JANUARY 13, 2004

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Neurath, et al., "Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit NF-kB abrogates established experimental colitis in mice", Nature Med., Vol. 2 (9), pp. 998-1004 (1996)
	AS	Marok, et al., "Activation of the Transcription Factor Nuclear Factor-kB In Human Inflame Synovial Tissue", Arthritis & Rheum., Vol. 39 (4), pp. 583-591 (1996)
	AT	Cabannes, et al., "Mutations in the <i>IkB</i> gene in Hodgkin's disease suggest a tumour suppressor role for <i>IkB</i> , Oncogene, Vol. 18, pp. 3063-3070 (1999)


**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0284 NP  
APPLICATION NO.  
10/755,889  
APPLICANT  
NADLER ET AL.  
FILING DATE  
JANUARY 13, 2004

Group

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Rayet, et al., "Aberrant <i>rel/nfkb</i> genes and activity in human cancer", <i>Oncogene</i> , Vol. 18, pp. 6938-6947 (1999)
2AB	Brown, et al., "Control of I $\kappa$ B-a Proteolysis by Site-Specific, Signal-Induced Phosphorylation", Vol. 267, pp. 1485-1488 (1995)
2AC	Hiscott, et al., "Hostile takeovers: viral appropriation of the NF-kB pathway", Vol. 107 (2), pp. 143-151 (2001)
2AD	Yamamoto, et al., "Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer", <i>J. Clin. Inves.</i> , Vol. 107 (2), pp. 135-142 (2001)
2AE	Miagkov, et al., "NF-kB activation provides the potential link between inflammation and hyperplasia in the arthritic joint", <i>Proc. Natl. Acad. Sci.</i> , Vol. 95, pp. 13859-13864 (1998)
2AF	Bondeson, et al., "Defining therapeutic targets by using adenovirus: Blocking NF-kB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators", <i>Proc. Natl. Acad. Sci.</i> , Vol. 96, pp. 5668-5673, (1999)
2AG	Christman, et al., "The Role of Nuclear Factor -k B in Pulmonary Diseases", <i>Chest</i> , Vol. 117, pp. 1482-1487 (2000)
2AH	Baldwin, Albert S., Jr., "The NF-kB and I $\kappa$ B Proteins: New Discoveries and Insights", <i>Annu. Rev. Immunol.</i> , Vol. 14, pp. 649-681 (1996)
2AI	Smahl, et al., "Genomic rearrangement in NEMO impairs NF-kB activation and is a cause of incontinentia pigmenti", <i>Nature</i> , Vol. 405, pp. 466-472 (2000)
2AJ	Whiteside, et al., "I kappa B epsilon, a novel member of the I $\kappa$ B family, controls RelA and cRel NF-kB activity," <i>EMBO J.</i> , Vol. 16 (6), pp. 1413-1426 (1997)
2AK	Jain, et al., "Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia", <i>Nature immunol.</i> , Vol. 2 (3), pp. 223-228 (2001)
2AL	Doffinger, et al., "X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kB signaling", <i>Nature Genetics</i> , Vol. 27, pp. 277-285 (2001)
2AM	Baeuerle, et al., "NF-kB: Ten Years After", <i>Cell</i> , Vol. 87, pp. 13-20 (1996)
2AN	Siebenlist, et al., "Structure, Regulation and Function of NF-kB", <i>Cell. Biol.</i> , Vol. 10, pp. 405-455 (1994)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.